* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Hypertension
Neuropharmacology wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Drug discovery wikipedia , lookup
Discovery and development of beta-blockers wikipedia , lookup
Prescription costs wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Hypertension (HT) High Blood Pressure (HBP) slide 1 Introduction • Definition: Hypertension is defined as elevated arterial blood pressure. • Hypertension is one of the most common disease in the world • In our country, 160 million people over the age of 15 have established or borderline HP • HP Essential HP (95%) Secondary HP (5%) slide 2 Etiology • Genetic • Environment Dietary: Salt intake Alcohol intake Obesity Infant dysnutrition slide 3 Pathogenesis 1. High activity of the SNS (Sympathetic Nervous System) 2. RAAS (Renin-Angiotension Aldosterone System) 3. Renal Sodium Handling 4. Vascular Remodelling 5. Endothelial Cell Dysfunction 6. Insulin Resistance slide 4 The pathological changes of small artery slide 6 The pathological change of the Heart Left ventricular hypertrophy (LVH) Heart failure Coronary artery atherosclerosis Myocardial infarction slide 7 Pathological change of the Brain Stroke: Ischemic stroke Hemorrhagic stoke Arterial Aneurysm slide 8 Pathological change of Renal Hypertension induced nephrosclerosis, atrophy of renal cortex slide 9 Clinical Features • The blood pressure varies widely over time, depending on many variables, including SNS activity, posture, state of hydration, and skeletal muscle tone. • Symptoms: Always asymptomatic Symptoms often attributed to hypertension: headache, tinnitus, dizziness, fainting slide 10 Clinical Features • Complications of Hypertension Heart: LVH, CHD,HF Brain: TIA, Stroke Renal: Microalbuminuria, renal dysfunction Ratinopathy slide 11 Laboratory Examination • Blood pressure measurement: Clinic Blood Pressure Home Blood Pressure Ambulatory monitoring slide 12 Ambulatory Measurement • Ambulatory monitoring can provide: – readings throughout day during usual activities – readings during sleep to assess nocturnal changes – measures of SBP and DBP load – Exclude white coat or office hypertension • Ambulatory readings are usually lower than in clinic (hypertension is defined as > 135/85 mm Hg) slide 13 Laboratory Examination • • • • • • Urinalysis Blood examination Chest X Ray EKG UCG (Ultrasound cardiography) Retina examination slide 14 slide 15 slide 16 slide 17 The Keith-Wagner Criteria (change in retina) KW I: Minimal arteriolar narrowing, irregularity of the lumen, and increased light reflex KW II: More marked narrowing and irregularity with arteriovenous nicking (crossing defects) KW III: Flame-shaped hemorrhages and exudates in addition to above arteriolar changes KW IV: Any of the above with addition of papilledema slide 18 Pepilledema Flame shaped hemorrhage slide 19 Diagnosis & Differential Diagnosis slide 20 Classification of blood pressure for adult Category Normal High normal Hypertension Stage 1 Stage 2 Stage 3 Systolic HBP SBP (mmHg) DBP (mmHg) < 120 < 80 120-139 80-89 ≥140 140-159 160-179 ≥180 ≥90 90-99 100-109 ≥110 ≥140 < 90 When the SBP and DBP fall into different categories, use the higher category slide 21 Evaluation Objectives • To identify cardiovascular risk factors • To assess presence or absence of target organ damage • To identify other causes of hypertension These evaluation may used in stratification of the hypertension patients slide 22 Cardiovascular Risk Factors • • • • • • • Blood pressure Age Gender Dyslipidemia Abdomen Obesity Family History of cardiovascular disease CRP ≥1mg/dl slide 23 Target Organ Damage • • • • Left ventricular hypertrophy Echo shows IMT of carotid artery Plasma creatinine slight elevation Microalbuminuria slide 24 Associated Clinical Condition • Cerebrovascular diseases: Stroke, TIA • Heart diseases: MI, AP, CHF, Coronary artery revasculation • Kidney diseases: DN, Dysfunction of the kidney, Proteinuria, CRF • Diabetes • Peripheral artery disease • Retinopathy slide 25 Evaluation Components • Medical history • Physical examination • Routine laboratory tests slide 26 Stratification of Hypertension patients Blood Pressure risk factors & Disease History Grade I Grade II Grade III I . No risk factors Low risk Med risk High risk II. 1-2 risk factors Med risk Med risk Very high risk III. 3 or more risk factors or TOD or diabetes IV. ACC High risk High risk Very high risk Very high risk Very high risk Very high risk TOD-Target Organ Damage; ACC-Associated Clinical Conditions slide 27 Differential Diagnosis Should exclude Secondary Hypertension slide 28 Secondary Hypertension Common Causes • Renal Glomerulonephritis Pyelonephritis Obstructive nephropathy Collagen diseases, Congenital diseases Diabetes nephropathy Renal tumor---- renin secreting tumor • Pheochromocytoma • Primary aldosteronism slide 29 Phenochromocytoma • • • • • • Ganglion-neurotomas and neuroblastomas Excretion of large amounts of catecholamines 90% arise in the adrenal medulla 10% are malignant. Paroxymal or persist HT Clinic features: Headache, sweating, palpitations, nervousness, weight loss, hypermetabolism, orthostatic hypotension, severe presser response slide 30 Primary Aldosteronism • • • • • • Mild or moderate hypertension Hypokalemia, muscle weakness, paralysis Polyuria, nocturia and polydipsia, Hypochloremic alkalosis Urine aldosterone elevation Plasma renin active decrease slide 31 Secondary Hypertension • • • • • Obstructive Sleep Apnea (OSA) Renal artery stenosis Cushing’s syndrome Coarctation of the aorta Drug-induced: NSAIDs; Prophylactic; Mineralocorticoids; Epogen Sympathomimetic medications; Monoamine oxidase inhibitors; Immuno-inhibitors; slide 32 Therapy slide 33 Goal of Hypertension Management • < 140/90 mm Hg • With Diabetes or kidney dysfunction: <130/80mmHg – To reduce morbidity and mortality of cerebral and cardiovascular complications. – Controlling other cardiovascular risk factors slide 34 Lifestyle Modifications • • • • • • Stop smoking Limit alcohol intake Lose weight or keep fit Suitable diet Increase aerobic physical activity Decrease psychological stress slide 35 Principle of Drug Therapy • Drug therapy should be individually • A low dose of initial drug therapy • Combination therapies may provide additional efficacy with fewer adverse effects. • Optimal formulation should provide 24-hour efficacy with once-daily dose. slide 36 Antihypertensive Drugs • Diuretics • • • • ß-Adrenergic receptor blockers (BB) Calcium channel blockers (CCB) ACE inhibitors (ACEI) Angiotensin II receptor blockers (ARB) slide 37 Algorithm for Treatment of Hypertension Hypertension patient Lifestyle Modifications Not at Goal Blood Pressure Initial Drug Choices slide 38 Algorithm for Treatment of Hypertension (continued) Initial Drug Choices No associated clinical condition I stage hypertension: Diuretics, BB,CCB,ACEI,ARB Associated clinical condition II stage hypertension: Two drugs combination therapy Choice the drugs according to ACC Not at Goal Blood Pressure Increase dosage or add another agent from different class slide 39 Drug choices in hypertension patient associated with clinical condition Drug ACC Diuretics BB ACEI ARB CCB Antialdosterone √ √ √ √ HF √ √ √ MI √ √ √ √ CAD √ √ √ √ √ DM √ √ CRF √ √ Stroke slide 40 Combination Therapies • May provide additional efficacy with fewer adverse effects. • Diuretics as the basement drug in combination therapy. Diuretics ---- ACEI / ARB Diuretics ---- BB Diuretics ---- CCB • CCB as the basement drug in combination therapy CCB ---- ACEI CCB ---- BB • Others: Three drugs combination slide 41 Causes for Inadequate Response to Drug Therapy • Incorrect measurement of the BP • Volume overload or Pseudo-resistance • Drug-related causes • Associated conditions slide 42 Hypertensive crisis • Hypertensive Emergencies and Urgencies • Emergencies: The blood pressure is elevated severely and associated with target organ damage, such as hypertensive encephalopathy, AMI, pulmonary edema, require immediate blood pressure reduction. • Urgencies: The blood pressure is elevated severely but no target organ damage has acute target organ damage. • Fast-acting drugs are available. slide 43 Drugs Available for Hypertensive Crisis Vasodilators Adrenergic Inhibitors •Nitroprusside •Labetalol •Nicardipine •Esmolol •Nitroglycerin •Phentolamine •Hydralazine slide 44 Case 1 Male 29 years old Blood pressure elevated for two years With paroxysmal dizziness, blurred vision, sweating and palpitation BP: 160-180/90-100mmHg HR: 100-120 bpm When the patient with symptoms, the BP would elevate to 240-260/120-130mmHg, and HR increase to 130-150 bpm. slide 45 Physical examination: BP: 165/100mmHg HR: 112 bpm No positive sign in chest examination Can find a mass at right abdomen, if press on it the BP of the patient elevated to 250/120mmHg, and the HR increased to 145 bpm. slide 46 Laboratory test: Blood routine, Urinalysis, Blood biochemistry are normal Plasma renine activation: 0.93ng/ml.h (0.93-6.56) AT II: 51.5pg/ml ↓ (55.3-115.3) Aldosterone: 129.4pd/ml (63-239.6) NE: 33.40pmol/ml ↑↑ (0.51-3.26) 12-lead electrocardiogram: High voltage of LV Chest X ray: Normal slide 47 CT scan of abdomen: Found a mass at right adrenal Diagnosis as Phenochromocytoma slide 48 Case 2 Male, 65 years old Hypertension history for 30 years Headache, blurred vision, vomiting for 2 hours Paralysis of left side body BP: 220/130mmHg HR: 106 bpm CT scan of the head: Normal slide 49 Diagnosis: Hypertensive crisis Therapy: Controlled the BP, using fast-acting drug,such as Nitroprusside, Labetalol The reduction of BP should less than 25% in 24 hours BP ≥ 160/100mmHg in 48 hours slide 50 Summary • Specific therapy for patients with LVF, CAD, and HF. ACEI can be used for all type patients. • In older persons, diuretics and CCB are preferred. • Many patients need combination therapy. • Goal of the patients with renal insufficiency with proteinuria (>1 g/day): 125/75 mmHg; (< 1 g/day): 130/80 mmHg. • Patients with diabetes should be treated to a therapy goal of below 130/80 mm Hg. slide 51